<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Anogenital Warts ‚Äì One‚ÄëPage Clinical Algorithm (Primary Care)</title>
  <meta name="description" content="Fast reference algorithm for assessment and management of anogenital warts in primary care (CKS/BASHH aligned, May 2024)." />
  <style>
    :root{
      --bg: #0b0d14;
      --panel: #11131c;
      --panel-2: #171a24;
      --text: #e9ecf1;
      --muted: #aeb6c2;
      --accent: #5ac8fa; /* subtle cyan */
      --accent-2: #7b61ff; /* violet */
      --ok: #34d399; /* green */
      --warn: #f59e0b; /* amber */
      --danger: #ef4444; /* red */
      --chip: #212636;
      --shadow: 0 10px 30px rgba(0,0,0,.35);
      --radius: 16px;
    }
    @media (prefers-color-scheme: light){
      :root{
        --bg: #f7f8fb; --panel: #ffffff; --panel-2:#f0f3f9; --text:#0e141b; --muted:#4b5563; --chip:#eef2f9;
        --shadow: 0 8px 24px rgba(16,24,40,.08);
      }
    }
    html,body{height:100%}
    body{
      margin:0; background: radial-gradient(1200px 600px at 20% -10%, rgba(122,101,255,.08), transparent 60%),
      radial-gradient(900px 500px at 110% 0%, rgba(90,200,250,.08), transparent 50%), var(--bg);
      color:var(--text); font: 500 16px/1.6 system-ui, -apple-system, Segoe UI, Roboto, Inter, "Helvetica Neue", Arial, "Noto Sans", "Apple Color Emoji", "Segoe UI Emoji";
      -webkit-font-smoothing: antialiased; text-rendering: optimizeLegibility;
    }
    header{
      position:sticky; top:0; z-index:10; backdrop-filter: saturate(140%) blur(8px);
      background: linear-gradient(90deg, rgba(123,97,255,.18), rgba(90,200,250,.18));
      border-bottom: 1px solid rgba(255,255,255,.08);
    }
    .wrap{max-width:1100px; margin:0 auto; padding: 20px clamp(16px, 3vw, 28px);}    
    .hero{display:flex; align-items:center; gap:18px;}
    .logo{width:44px;height:44px;border-radius:12px;background:linear-gradient(135deg,var(--accent-2),var(--accent));
      display:grid;place-items:center; box-shadow: var(--shadow);}    
    .logo svg{filter:drop-shadow(0 3px 8px rgba(0,0,0,.25))}
    .title{display:flex;flex-direction:column;gap:2px}
    .title h1{margin:0; font-weight:800; letter-spacing:.2px; font-size: clamp(18px, 2.2vw, 26px)}
    .subtitle{font-size:14px; color:var(--muted)}

    .bar{display:flex; gap:10px; flex-wrap:wrap; margin-top:10px}
    .chip{background:var(--chip); color:var(--text); padding:6px 10px; border-radius:999px; font-size:12px; border:1px solid rgba(255,255,255,.08)}
    .spacer{flex:1}
    .btn{appearance:none; border:0; border-radius:10px; padding:10px 14px; font-weight:700; cursor:pointer; color:#0b0d14; background:linear-gradient(180deg, #fff, #e8ecf7); box-shadow: var(--shadow)}
    .btn:active{transform:translateY(1px)}

    main{padding: 28px 0 60px}
    .grid{display:grid; grid-template-columns: repeat(12, 1fr); gap:18px}
    .card{grid-column: span 12; background:linear-gradient(180deg,var(--panel),var(--panel-2)); border:1px solid rgba(255,255,255,.06);
      border-radius: var(--radius); padding:18px 18px 16px; box-shadow: var(--shadow)}
    .card h2{margin:0 0 8px; font-size: clamp(16px, 2vw, 20px)}
    .card h3{margin:14px 0 8px; font-size: 15px}
    .kicker{display:flex; align-items:center; gap:8px; color:var(--muted); font-size:12px}
    .kicker .dot{width:8px;height:8px;border-radius:50%; background: var(--accent)}
    .pill{display:inline-block; font-size:11px; padding:3px 8px; border-radius:999px; background:rgba(90,200,250,.12); border:1px solid rgba(90,200,250,.45)}
    ul,ol{margin:8px 0 0 18px}
    li{margin:4px 0}
    .col-6{grid-column: span 6}
    .col-4{grid-column: span 4}
    .col-8{grid-column: span 8}
    .em{color:var(--accent)}
    .badges{display:flex; gap:8px; flex-wrap:wrap}

    .table{width:100%; border-collapse: collapse; margin-top:10px; font-size:14px}
    .table th,.table td{padding:10px 12px; border-bottom:1px solid rgba(255,255,255,.08); text-align:left}
    .table th{font-weight:800; color:var(--muted)}
    .callout{display:flex; gap:10px; align-items:flex-start; background:linear-gradient(180deg, rgba(34,197,94,.12), rgba(34,197,94,.06));
      border: 1px solid rgba(34,197,94,.35); padding:10px 12px; border-radius:12px; margin-top:8px}
    .warn{background:linear-gradient(180deg, rgba(245,158,11,.12), rgba(245,158,11,.06)); border-color: rgba(245,158,11,.35)}
    .danger{background:linear-gradient(180deg, rgba(239,68,68,.12), rgba(239,68,68,.06)); border-color: rgba(239,68,68,.35)}

    details{background:linear-gradient(180deg,var(--panel),var(--panel-2)); border:1px dashed rgba(255,255,255,.14); border-radius:12px; padding:10px 12px; margin-top:8px}
    summary{cursor:pointer; list-style:none; font-weight:700}
    summary::-webkit-details-marker{display:none}
    summary .chev{transition: transform .2s ease}
    details[open] summary .chev{transform: rotate(90deg)}

    footer{color:var(--muted); font-size:12px; margin-top:22px}

    /* Responsive */
    @media (min-width: 860px){
      .col-6{grid-column: span 6}
      .col-4{grid-column: span 4}
      .col-8{grid-column: span 8}
    }

    /* Print styles ‚Äì fits neatly on A4 */
    @media print{
      header{position:static; background:none; border:none}
      .btn,.bar .chip.print-hide{display:none !important}
      body{background:white; color:black}
      .card{box-shadow:none; border: 1px solid #ddd; background:white}
      .wrap{max-width:unset; padding: 0 8mm}
      .grid{gap:10px}
      .table th,.table td{border-color:#ddd}
      details{border-color:#bbb}
    }
  </style>
</head>
<body>
  <header>
    <div class="wrap">
      <div class="hero">
        <div class="logo" aria-hidden="true">
          <svg width="26" height="26" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg" role="img" aria-label="Algorithm icon">
            <path d="M4 6h6v4H4V6Z" stroke="white" stroke-width="1.6"/>
            <path d="M14 4h6v6h-6V4Z" stroke="white" stroke-width="1.6"/>
            <path d="M10 8h4" stroke="white" stroke-width="1.6"/>
            <path d="M4 14h6v4H4v-4Z" stroke="white" stroke-width="1.6"/>
            <path d="M10 16h4" stroke="white" stroke-width="1.6"/>
            <circle cx="18" cy="18" r="3.2" stroke="white" stroke-width="1.6"/>
          </svg>
        </div>
        <div class="title">
          <h1>Anogenital Warts ‚Äî Primary Care Algorithm</h1>
          <div class="subtitle">CKS/BASHH aligned quick reference ‚Ä¢ Last revised: <strong>May¬†2024</strong> ‚Ä¢ Intended for ‚â•¬†13¬†years</div>
          <div class="bar">
            <span class="chip">Clinical diagnosis</span>
            <span class="chip">Screen for STIs</span>
            <span class="chip">High relapse ‚ü∂ set expectations</span>
            <span class="spacer"></span>
            <button class="btn" onclick="window.print()">üñ®Ô∏è Print / Save PDF</button>
          </div>
        </div>
      </div>
    </div>
  </header>

  <main class="wrap">
    <div class="grid">

      <!-- Overview -->
      <section class="card col-8">
        <div class="kicker"><span class="dot"></span> Summary</div>
        <h2>Fast Overview</h2>
        <ul>
          <li><strong>Benign HPV lesions</strong> (commonly types 6/11). Many are asymptomatic.</li>
          <li><strong>Spontaneous resolution</strong> in ~30% by 6¬†months. Treatment speeds clearance but <em>does not eradicate HPV</em>.</li>
          <li><strong>Aim</strong>: remove visible warts; reduce symptoms and psychosocial impact.</li>
        </ul>
        <div class="callout"><strong>Key:</strong>&nbsp;&nbsp;Soft/non‚Äëkeratinised ‚Üí podophyllotoxin/TCA ‚Ä¢ Keratinised or low volume ‚Üí consider ablative ‚Ä¢ Imiquimod works for both types.</div>
      </section>

      <section class="card col-4">
        <div class="kicker"><span class="dot"></span> Navigation</div>
        <h2>Quick Jump</h2>
        <div class="badges">
          <a class="pill" href="#assessment">Assessment</a>
          <a class="pill" href="#referral">Referral</a>
          <a class="pill" href="#management">Management</a>
          <a class="pill" href="#treatment">Treatment</a>
          <a class="pill" href="#special">Special Groups</a>
          <a class="pill" href="#followup">Follow‚Äëup</a>
          <a class="pill" href="#howto">How‚Äëto Apply</a>
          <a class="pill" href="#ddx">Differentials</a>
        </div>
      </section>

      <!-- Assessment -->
      <section id="assessment" class="card col-6">
        <div class="kicker"><span class="dot"></span> Step¬†1</div>
        <h2>Initial Assessment</h2>
        <ul>
          <li><strong>Clinical diagnosis</strong>; biopsy only if atypical (pigmented, bleeding, ulcerated, fixed) or uncertain.</li>
          <li><strong>Sexual history</strong>: new/multiple partners, barrier use.</li>
          <li><strong>Symptoms</strong>: discharge, bleeding, dysuria, pruritus, pain, irritation, altered urine stream.</li>
          <li><strong>Examination</strong>: external genitalia, perianal, adjacent areas; speculum if introitus lesions/other vulvovaginal symptoms; proctoscopy if anal symptoms or margin lesions; meatoscopy if needed.</li>
          <li>Consider <strong>pregnancy</strong>, <strong>HIV</strong>, <strong>immunosuppression</strong>; examine extra‚Äëgenital sites if indicated.</li>
        </ul>
      </section>

      <!-- Referral -->
      <section id="referral" class="card col-6">
        <div class="kicker"><span class="dot"></span> Step¬†2</div>
        <h2>Red Flags & Referral</h2>
        <ul>
          <li>Refer to sexual health if diagnosis uncertain or specialist care preferred.</li>
          <li><strong>Refer</strong> if: recurrent perianal; urinary symptoms; suspected malignancy/intraepithelial neoplasia; immunosuppressed (incl. HIV); cervical/intra‚Äëmeatal/intra‚Äëanal warts; pregnancy; child; elderly.</li>
          <li><strong>Safeguarding</strong>: consider abuse in children (<13) and assess context in 13‚Äì17¬†yrs; follow local procedures.</li>
        </ul>
        <div class="callout warn">Partner tracing <strong>not recommended</strong> unless other STIs present.</div>
      </section>

      <!-- Management -->
      <section id="management" class="card col-6">
        <div class="kicker"><span class="dot"></span> Step¬†3</div>
        <h2>Management Principles</h2>
        <ul>
          <li><strong>Screen for STIs</strong> (esp. &lt;25¬†yrs or if symptoms).</li>
          <li><strong>Counsel</strong>: multiple attempts often required; failure/relapse common; skin reactions likely; condoms &amp; smoking cessation improve outcomes.</li>
          <li><strong>Reassure</strong>: long latency (weeks‚Äìmonths) ‚Üí does not imply recent infidelity.</li>
          <li><strong>Cervical screening</strong>: routine intervals unchanged.</li>
        </ul>
      </section>

      <!-- Treatments -->
      <section id="treatment" class="card col-6">
        <div class="kicker"><span class="dot"></span> Step¬†4</div>
        <h2>Treatment Options</h2>
        <h3>Home (not in pregnancy/children)</h3>
        <ul>
          <li><strong>Podophyllotoxin</strong> 0.5% solution or 0.15% cream ‚Üí best for <em>soft, non‚Äëkeratinised</em> external lesions. Solution slightly more effective; cream easier for access.</li>
          <li><strong>Imiquimod 5% cream</strong> ‚Üí suitable for <em>keratinised &amp; non‚Äëkeratinised</em> external/perianal; <em>not</em> for internal use.</li>
          <li><strong>Sinecatechins 10% ointment</strong> ‚Üí adults ‚â•18, external only; avoid if immunocompromised.</li>
        </ul>
        <h3>Clinic / Specialist</h3>
        <ul>
          <li><strong>Ablative</strong>: cryotherapy, excision, electrocautery ‚Äî good for small number/low volume lesions (any type).</li>
          <li><strong>Topical acids</strong>: trichloroacetic acid (80‚Äì90%), nitrizinc complex.</li>
        </ul>
        <h3>Not Recommended</h3>
        <ul>
          <li>Podophyllin (unstandardised), interferon. 5‚ÄëFU and KOH are not standard for anogenital warts.</li>
        </ul>
        <h3>Picking First‚ÄëLine</h3>
        <ul>
          <li>Match to <strong>type</strong>: soft/non‚Äëkeratinised ‚Üí podophyllotoxin/TCA; keratinised ‚Üí ablative ¬± imiquimod.</li>
          <li>Consider <strong>site</strong>, <strong>number/volume</strong>, prior response, availability, cost, preference, comorbids.</li>
        </ul>
        <table class="table" aria-label="Clearance and recurrence rates">
          <thead><tr><th>Agent</th><th>Clearance*</th><th>Recurrence</th></tr></thead>
          <tbody>
            <tr><td>Imiquimod 5% cream</td><td>35‚Äì68%</td><td>6‚Äì26%</td></tr>
            <tr><td>Podophyllotoxin 0.5% solution</td><td>45‚Äì83%</td><td>13‚Äì100%</td></tr>
            <tr><td>Podophyllotoxin 0.15% cream</td><td>43‚Äì70%</td><td>6‚Äì55%</td></tr>
            <tr><td>Sinecatechins 10% ointment</td><td>47‚Äì59%</td><td>11‚Äì57%</td></tr>
          </tbody>
        </table>
        <div class="subtitle">*Intent‚Äëto‚Äëtreat ranges; real‚Äëworld responses vary.</div>
      </section>

      <!-- Special Groups -->
      <section id="special" class="card col-6">
        <div class="kicker"><span class="dot"></span> Step¬†5</div>
        <h2>Special Groups</h2>
        <h3>Pregnancy</h3>
        <ul>
          <li>May enlarge; often delay therapy until postpartum (frequent spontaneous resolution within 6¬†weeks postpartum).</li>
          <li>Avoid <em>topicals</em> (podophyllotoxin, imiquimod, sinecatechins). Prefer <strong>cryotherapy</strong> or <strong>TCA</strong> if needed.</li>
          <li>Low risk of vertical HPV transmission / recurrent respiratory papillomatosis.</li>
        </ul>
        <h3>Immunocompromised (incl. HIV)</h3>
        <ul>
          <li>Higher burden, lower spontaneous clearance, higher SCC risk, more recurrences.</li>
          <li>May need <strong>longer</strong> or <strong>combined</strong> regimens; consider surgical then adjunct therapy.</li>
        </ul>
        <h3>Children / Adolescents</h3>
        <ul>
          <li>Assess for non‚Äësexual vs sexual transmission context; safeguarding as indicated; refer to paediatrics/sexual health.</li>
        </ul>
      </section>

      <!-- Follow up -->
      <section id="followup" class="card col-6">
        <div class="kicker"><span class="dot"></span> Step¬†6</div>
        <h2>Follow‚Äëup</h2>
        <ul>
          <li>Review after treatment course to confirm clearance and plan next steps.</li>
          <li><strong>Change therapy</strong> if intolerant or &lt;50% response by 4‚Äì5¬†weeks (<em>imiquimod</em>: re‚Äëassess at 8‚Äì12¬†weeks).</li>
          <li>Optional review at ~3¬†months post‚Äëclearance (recurrences common then).</li>
          <li>Closer follow‚Äëup if immunocompromised.</li>
        </ul>
      </section>

      <!-- How-to apply -->
      <section id="howto" class="card col-12">
        <div class="kicker"><span class="dot"></span> Technique</div>
        <h2>How‚Äëto Apply (Patient Instructions)</h2>
        <details>
          <summary><span class="chev">‚ñ∂</span> Imiquimod 5% cream</summary>
          <ul>
            <li>Thin layer <strong>3√ó/week at bedtime</strong> (e.g., Mon/Wed/Fri) on external genital/perianal warts only.</li>
            <li>Leave on <strong>6‚Äì10¬†hours</strong>, then wash off with mild soap/water.</li>
            <li>Continue until clearance or <strong>max 16¬†weeks</strong> per episode.</li>
            <li>Avoid normal/broken skin; wash hands before/after; avoid unprotected sex soon after application (irritant; may weaken condoms/diaphragms).</li>
            <li>Expect delayed response; inflammation early on is common ‚Äî if severe, pause, allow to settle, then re‚Äëintroduce 1‚Äì2√ó/week and titrate.</li>
            <li>Warn about possible <strong>permanent hypo/hyper‚Äëpigmentation</strong> with overuse; avoid excess amounts.</li>
          </ul>
        </details>
        <details>
          <summary><span class="chev">‚ñ∂</span> Podophyllotoxin 0.5% solution / 0.15% cream</summary>
          <ul>
            <li>Apply <strong>twice daily for 3¬†days</strong>, then <strong>4¬†days off</strong>; repeat weekly as needed.</li>
            <li>Max courses: <strong>4 √ó 3‚Äëday</strong> (cream) ‚Ä¢ <strong>5 √ó 3‚Äëday</strong> (0.5% solution).</li>
            <li>External, soft non‚Äëkeratinised lesions only; avoid normal skin and open wounds.</li>
            <li>Local irritation common by day¬†2‚Äì3 and improves post‚Äëcourse; stop if significant soreness/ulceration.</li>
            <li>Do <strong>not</strong> exceed recommended amounts ‚Äî systemic toxicity possible with overuse.</li>
          </ul>
        </details>
        <details>
          <summary><span class="chev">‚ñ∂</span> Sinecatechins 10% ointment</summary>
          <ul>
            <li>Apply small amount (~0.5¬†cm strand) to each wart <strong>3√ó/day</strong>; leave thin film. Do not wash off between doses.</li>
            <li>Continue until full clearance or <strong>max 16¬†weeks</strong>; adults ‚â•¬†18 only; avoid if immunocompromised.</li>
            <li>Wash off before condoms/diaphragms (can weaken latex). Local irritation expected initially.</li>
          </ul>
        </details>
        <div class="callout">Demonstrate lesion locations and application technique to reduce undertreatment.</div>
      </section>

      <!-- Differentials -->
      <section id="ddx" class="card col-12">
        <div class="kicker"><span class="dot"></span> Consider</div>
        <h2>Key Differentials</h2>
        <ul>
          <li><strong>Pearly penile papules</strong> (benign, corona/sulcus rings).</li>
          <li><strong>Molluscum contagiosum</strong> (umbilicated papules).</li>
          <li><strong>Condylomata lata</strong> (secondary syphilis; moist plaques + systemic features).</li>
          <li><strong>Carcinoma in¬†situ</strong> (multifocal erythematous/pigmented macules/plaques; smooth/velvety).</li>
          <li>Other benign: skin tags, seborrhoeic keratoses, epidermoid cysts, hidradenoma papilliferum, sebaceous glands (foreskin/vulva).</li>
        </ul>
      </section>

      <section class="card col-12">
        <div class="kicker"><span class="dot"></span> Tips</div>
        <h2>Consultation Prompts</h2>
        <ul>
          <li>Document <strong>type/site/number/volume</strong> of lesions; photograph if service permits.</li>
          <li>Offer <strong>STI screening</strong> (NAATs; HIV, syphilis, hepatitis as indicated).</li>
          <li>Discuss <strong>expectations</strong>, <strong>side‚Äëeffects</strong>, and <strong>recurrence</strong> risk before choosing therapy.</li>
          <li>Provide written patient advice; consider psychological support if distress present.</li>
        </ul>
        <footer>For full context see local sexual health guidelines. This quick reference summarises CKS/BASHH‚Äëaligned recommendations (May¬†2024).</footer>
      </section>

    </div>
  </main>
</body>
</html>